Danaher Corporation $DHR Shares Purchased by Elmwood Wealth Management Inc.

Elmwood Wealth Management Inc. raised its holdings in Danaher Corporation (NYSE:DHR) by 73.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,986 shares of the conglomerate’s stock after buying an additional 4,222 shares during the quarter. Elmwood Wealth Management Inc.’s holdings in Danaher were worth $2,212,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Veery Capital LLC lifted its holdings in shares of Danaher by 3.1% during the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock worth $350,000 after acquiring an additional 48 shares during the period. Studio Investment Management LLC boosted its position in shares of Danaher by 3.3% in the second quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock worth $302,000 after acquiring an additional 51 shares during the last quarter. JDH Wealth Management LLC grew its holdings in Danaher by 4.5% in the first quarter. JDH Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock valued at $240,000 after purchasing an additional 55 shares during the period. OLD Second National Bank of Aurora grew its holdings in Danaher by 0.5% in the first quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock valued at $2,297,000 after purchasing an additional 57 shares during the period. Finally, Adelphi Trust Co increased its position in Danaher by 2.5% during the third quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock worth $524,000 after purchasing an additional 57 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a strong earnings-surprise history and currently shows the two indicators—earnings estimate revisions and an Earnings ESP reading—that can signal another quarterly beat. Analysts expect earnings growth in the upcoming report. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: NVIDIA collaboration supports AI strategy: Danaher announced a partnership with NVIDIA to combine its scientific instruments, laboratory automation, workflow software and domain expertise with NVIDIA’s accelerated computing and AI technologies. The goal is to advance autonomous science and speed up scientific discovery, creating a potentially important long-term growth opportunity in life-science research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous laboratory plans: Danaher plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations expected in early 2027. The initiative could improve laboratory productivity and strengthen Danaher’s positioning in AI-enabled drug discovery, though meaningful revenue benefits are likely longer term. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained its $240 price target for DHR, indicating continued confidence in the company’s outlook but no new change in the valuation view. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board expansion: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings impact. Danaher Enhances Board With New Director Appointments

Danaher Trading Up 0.8%

DHR traded up $1.81 on Wednesday, reaching $224.65. 3,595,884 shares of the company’s stock were exchanged, compared to its average volume of 4,457,645. The company’s 50 day moving average is $212.41 and its 200-day moving average is $195.13. The company has a market cap of $157.93 billion, a price-to-earnings ratio of 39.90, a PEG ratio of 2.78 and a beta of 0.76. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.77 earnings per share. Equities analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s dividend payout ratio is presently 28.42%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. UBS Group initiated coverage on Danaher in a report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price objective for the company. The Goldman Sachs Group upped their price objective on Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Finally, Guggenheim increased their target price on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.